Multicenter, randomized, open label trial comparing the efficacy and safety of a basiliximab-based immunosuppressive regimen, immediate introduction of small doses of extended-release tacrolimus, mycophenolate sodium and steroids versus basiliximab, delayed introduction of small doses of extended-release tacrolimus, mycophenolate sodium and steroids in elderly patients with kidney transplants. [Ensayo multicéntrico, aleatorizado, abierto que compara la eficacia y seguridad de un régimen inmunosupresor basado en basiliximab, introducción inmediata de dosis reducidas de tacrolimus de liberación prolongada, micofenolato sódico y esteroides versus basiliximab, introducción retardada de dosis reducidas de tacrolimus de liberación prolongada, micofenolato sódico y esteroides en pacientes añosos trasplantados renales.]

Trial Profile

Multicenter, randomized, open label trial comparing the efficacy and safety of a basiliximab-based immunosuppressive regimen, immediate introduction of small doses of extended-release tacrolimus, mycophenolate sodium and steroids versus basiliximab, delayed introduction of small doses of extended-release tacrolimus, mycophenolate sodium and steroids in elderly patients with kidney transplants. [Ensayo multicéntrico, aleatorizado, abierto que compara la eficacia y seguridad de un régimen inmunosupresor basado en basiliximab, introducción inmediata de dosis reducidas de tacrolimus de liberación prolongada, micofenolato sódico y esteroides versus basiliximab, introducción retardada de dosis reducidas de tacrolimus de liberación prolongada, micofenolato sódico y esteroides en pacientes añosos trasplantados renales.]

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 13 Aug 2013

At a glance

  • Drugs Tacrolimus (Primary) ; Basiliximab; Corticosteroids; Mycophenolate sodium
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Aug 2013 Status changed from recruiting to discontinued.
    • 14 Oct 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top